GF Fund Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.52M Buy
30,479
+709
+2% +$180K 0.1% 111
2026
Q2
$8.96M Sell
29,770
-271
-0.9% -$81.7K 0.11% 111
2026
Q1
$9.9M Sell
30,041
-421
-1% -$143K 0.17% 93
2025
Q4
$12.1M Buy
30,462
+27,665
+989% +$12.2M 0.21% 85
2025
Q3
$1.28M Sell
2,797
-505
-15% -$206K 0.02% 185
2025
Q2
$1.08M Hold
3,302
– – 0.02% 207
2025
Q1
$892K Buy
3,302
+594
+22% +$153K 0.02% 210
2024
Q4
$637K Buy
+2,708
New +$712K 0.01% 215

Other funds holding ALNY

GF Fund Management's ALNY Position: Q3 2026 in Review

GF Fund Management increased its Alnylam Pharmaceuticals (ALNY) stake by 2.4% in Q3 2026, buying an estimated $180K and bringing the position to 30,479 shares worth $7.52M. The position accounts for 0.1% of the portfolio, ranked #111.

GF Fund Management first reported a position in ALNY in Q4 2024 and has held it in 8 quarters since. The position peaked at $12.1M in Q4 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • GF Fund Management held 30,479 shares of Alnylam Pharmaceuticals worth $7.52M as of Q3 2026.
  • GF Fund Management bought 709 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $180K.
  • Alnylam Pharmaceuticals made up 0.1% of GF Fund Management's portfolio in Q3 2026, its #111 holding.
  • GF Fund Management first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
  • GF Fund Management's Alnylam Pharmaceuticals position peaked at $12.1M in Q4 2025.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.